Cite

HARVARD Citation

    Siena, S. et al. (n.d.). 29LBA Entrectinib (RXDX-101), an oral pan-Trk, ROS1, and ALK inhibitor in patients with advanced solid tumors harboring gene rearrangements. European journal of cancer. pp. S724-S725. [Online]. 
  
Back to record